KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Non Operating Income (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Non Operating Income data on record, last reported at -$121000.0 in Q3 2025.

  • For Q3 2025, Non Operating Income fell 0.83% year-over-year to -$121000.0; the TTM value through Sep 2025 reached $270000.0, up 103.05%, while the annual FY2024 figure was -$390000.0, 96.9% up from the prior year.
  • Non Operating Income reached -$121000.0 in Q3 2025 per NKTR's latest filing, down from $260000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $19.8 million in Q2 2022 and bottomed at -$32.7 million in Q4 2021.
  • Average Non Operating Income over 5 years is -$3.1 million, with a median of -$121000.0 recorded in 2025.
  • Peak YoY movement for Non Operating Income: skyrocketed 2239.17% in 2022, then plummeted 700.25% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$32.7 million in 2021, then skyrocketed by 53.04% to -$15.4 million in 2022, then surged by 44.08% to -$8.6 million in 2023, then surged by 98.43% to -$135000.0 in 2024, then increased by 10.37% to -$121000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$121000.0 in Q3 2025, $260000.0 in Q2 2025, and $266000.0 in Q1 2025.